Neuronetics Wins 2023 Bell Seal for Workplace Mental Health
The Company is recognized for its commitment to employees’ well-beingMALVERN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:...
Mental Health
Join the Ride for Youth Mental Health: Help Make an Impact on Young Lives Today!
Canadian charity Jack.org and its supporters unite to raise funds that provide young people with the mental health education and...
Stella Opens Flagship PTSD Treatment Location in Chicago and Secures $7M in Funding
Funds raised from Sterling Partners will be used to further innovative research and expand access to cutting-edge careCHICAGO, May 09,...
Neuronetics Reports Record First Quarter 2023 Financial and Operating Results
MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or Neuronetics”) a commercial stage medical technology...
Neuronetics Receives MDSAP Certification and CE Mark Certification under New MDR
Achievement demonstrates Company’s commitment to rigorous standards for safe and effective productsMALVERN, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Neuronetics,...
Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam
Hebrew University of Jerusalem professor is an expert on obesity and metabolic syndrome Tel Aviv, Israel / Vancouver, Canada, May...
TFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental Health Sciences to Develop Dry Powder Formulations of Hyaluronan to Prevent and Treat Respiratory Diseases
FORT WORTH, Texas, May 04, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company...
VitalHub Announces Q1 2023 Conference Call Date
TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX:VHIBF) is pleased to announce...
Male Plus Is Calming Nerves and Restoring Fun to the Bedroom
The Belgian Health and Wellness Brand’s Natural Libido Enhancer Utilizes Ingredients That Calm the Mind While Revving Up the BodyFort...
Neuronetics Showcases New NeuroStar® TMS Findings at Clinical TMS Society Annual Meeting
Data highlights the Company’s commitment to advancing TMS and improving patient outcomesMALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Neuronetics,...
NeuroStar® Expands “Tap Into Possibility” Campaign in Honor of Mental Health Awareness Month
Campaign features patients’ experiences to support others with depression A Media Snippet accompanying this announcement is available by clicking on the...
Neuronetics Announces Lisa Metzner-Rosas as SVP, Chief Marketing Officer
Strategic role strengthens NeuroStar® Advanced Therapy commercialization teamMALVERN, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a...
Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month
One World Trade Center to be lit up in green in observance of Mental Health MonthNEW YORK, May 01, 2023...
Neuronetics Announces Expanded TMS Access through United HealthCare
UHC Medicare Advantage plans in NGS states expand access via NPPsMALVERN, Pa., April 28, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc....
Neuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call
MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on...
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
The application is for a novel psychedelic-based combination, of Clearmind's MEAI and SciSparc's Cannamide™ Tel Aviv, Israel / Vancouver, Canada,...
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression
The application refers to a novel psychedelic-based combination of Clearmind's MEAI and SciSparc's Cannamide™ TEL AVIV, Israel, April 21, 2023 (GLOBE NEWSWIRE)...
Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting
NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Baycrest’s Goal Management Training Now Offered Through Telus Health’s AbilitiCBT Platform
First large-scale digital roll out of Baycrest’s Goal Management Training will support mental rehabilitation for people across Canada and the...
Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease
Cuvrior™ now available in the US for the treatment of adult patients with stable Wilson disease who are de-coppered and...